UPDATE: Commonwealth Bank Upgrades ResMed to Buy Following Q4 Beat
Commonwealth Bank increased its rating on ResMed (NYSE: RMD) from Hold to Buy after the company reported strong fourth quarter results that beat expectations.
Commonwealth Bank commented, "Gross margin outperformance to continue: Gross margin expansion was driven by a combination of positive product mix (Bi-level, APAP and masks) and manufacturing efficiencies (S9 platform consolidation), which more than offset FX headwinds. We expect these two factors will continue to boost FY13 gross margins with: 1) ongoing transition to HST driving further growth in higher-margin APAP devices, 2) continued strength in high-end bi-level sales with the launch of the VPAP ST and STA models on the S9 platform, and 3) ongoing share gains in masks."
ResMed closed at $35.29 on Monday.
Latest Ratings for RMD
|Jul 2015||Morgan Stanley||Upgrades||Equal-weight||Overweight|
|Jun 2015||Barclays||Initiates Coverage on||Equal-weight|
|Apr 2015||Goldman Sachs||Downgrades||Buy||Neutral|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.